Cohort Study Investigating the Association Between Antichlamydial Antibody Positivity and ART Outcomes in Women With TFI

• Status: Active, not recruiting
• Trial end date: 2021-10-30
• Target enrollment: 0
• Participant gender: Female

Summary

In a prospective cohort study investigators will examine characteristics and clinical outcomes of treatment with ART in women with tubal factor infertility (TFI) with regard to seropositivity to antichlamydial antibodies.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology
• Treatments: Antibodies; Immunoglobulins

Criteria

Inclusion Criteria:

• Tubal factor infertility diagnosed by laparoscopy;

• Female age between 20-41 years;

• BMI 17,5-35 kg/m2;

• Early follicular phase follicle stimulating hormone (FSH) ≤15 IU/L

• Presence of viable spermatozoa in partner's sperm;

• Signed informed consent.

Exclusion Criteria:

• previous ovarian surgery;

• endometriosis;

• antimullerian hormone (AMH) level ≤0,3 ng/ml;

• hyper- or hypogonadotropic ovarian failure;

• severe male factor infertility;

• Pre-existing medical condition preventing or interfering with IVF treatment: any clinically significant systemic disease; inherited or acquires thrombophilia and thromboembolism; endocrine or metabolic abnormalities; moderate or severe impairment of renal or hepatic function; any oncological diseases in anamnesis; known history of recurrent miscarriage, abnormal karyotype of both partners; currently active pelvic inflammatory disease;

• Abnormal IVF screening tests: Papanicolaou (PAP) smear, Syphilis, HIV 1&2, Hepatitis B, Hepatitis C, Chlamydia, and Gonorrhea;

• Presence of uterine pathology: Asherman's Syndrome, endometrial polyps, nodus form of adenomyosis or uterine fibroids ≥3 mm in diameter;

• Visualization of ovarian cysts ≥25 mm, endometriomas or hydrosalpinx;

• One or more follicles ≥8 mm at the start of the COS protocol.